Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066. The Ridgebury-based firm reports that nearly double the percentage of patients with moderate to severe plaque psoriasis achieved clear or almost clear skin after 12 weeks of treatment with BI 655066 compared to ustekinumab (77.1% versus 40% of patients). BI 655066 had similar safety and tolerability to ustekinumab. The new data were presented recently at the 73rd annual meeting of the American Academy of Dermatology in San Francisco, Calif.